Headaches are a recognized adverse effect of GLP-1 receptor agonist therapy, though they vary in frequency across different medications, doses, and patient populations
We describe the evaluation and 12-week course of treatment, correlating the capillary beta-hydroxybutyrate/glucose ketone index (BHB/GKI) with time to remission and improvements in metabolic health and QoL
A qualified healthcare provider should evaluate your full lipid panel, cardiovascular risk profile, and medical history before treatment initiation
GLP-1 Starter Guide: Eligibility, Baseline Checks, and Ongoing Monitoring (DMV) Thinking about GLP-1 medications like semaglutide or tirzepatide
Rare metastases of differentiated thyroid carcinoma: pictorial review
Dosage and frequency are determined by the attending physician